It is made available under a CC-BY-NC-ND 4.0 International license .

### 1 The Contrasting Role of Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2)

# 2 Expression in SARS-CoV-2 Infection: A Cross-Sectional Study of People Tested for

- 3 COVID-19 in British Columbia
- 4
- 5 Authors: Aidan M. Nikiforuk<sup>1,4\*</sup> (MSc.), Kevin S. Kuchinski<sup>1,2\*</sup> (BSc.), David D.W. Twa<sup>2,3\*</sup>
- 6 (PhD), Christine D. Lukac<sup>1</sup> (MPH), Hind Sbihi<sup>1,4</sup> (PhD), C. Andrew Basham<sup>1,4</sup> (MSc.), Christian
  7 Steidl<sup>3</sup> (MD), Natalie A. Prystajecky<sup>1,2</sup> (PhD), Agatha N. Jassem<sup>1,2</sup> (PhD), Mel Krajden<sup>1,2</sup> (MD),
- 8 David M, Patrick<sup>1,4</sup> (MD) and Inna Sekirov<sup>1,2</sup> (PhD).
- 9
- 10 \*these authors contributed equally to the work.
- 11
- <sup>12</sup><sup>1</sup>British Columbia Centre for Disease Control, Vancouver, V5Z 4R4, British Columbia, Canada
- <sup>2</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,
   V6T 1Z4, British Columbia, Canada
- <sup>3</sup>British Columbia Cancer Research Centre, Vancouver, V5Z 1L3, British Columbia, Canada
- <sup>4</sup>School of Population and Public Health, University of British Columbia, Vancouver, V6T 1Z4,
- 17 British Columbia, Canada
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26 27
- 28
- 29
- 30
- 31
- 32
- 33 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41 **Corresponding Author:** Dr. Inna Sekirov MD/ PhD, British Columbia Centre for Disease
- 42 Control, Vancouver, British Columbia, Canada, V5Z 4R4 and Department of Pathology and
- 43 Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada,
- 44 V6T 1Z4.
- 45 email: <u>inna.sekirov@bccdc.ca</u>
- 46

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 47 Summary

#### 48

49 Background

Angiotensin converting enzyme 2 (*ACE2*) serves as the host receptor for SARS-CoV-2, with a critical role in viral infection. We aim to understand population level variation of nasopharyngeal *ACE2* expression in people tested for COVID-19 and the relationship between *ACE2* expression and SARS-CoV-2 viral RNA load, while adjusting for expression of the complementary protease, Transmembrane serine protease 2 (*TMPRSS2*), soluble *ACE2*, age, and biological sex.

56

### 57 Methods

A cross-sectional study of n=424 participants aged 1-104 years referred for COVID-19 testing was performed in British Columbia, Canada. Participants who tested negative or positive for COVID-19 were matched by age and biological sex. Viral and host gene expression was measured by quantitative reverse-transcriptase polymerase chain reaction. Bivariate analysis and multiple linear regression were performed to understand the role of nasopharyngeal *ACE2* expression in SARS-CoV-2 infection. The *ACE2* gene was targeted to measure expression of transmembrane and soluble transcripts.

65

66 Findings

67 Analysis shows no association between age and nasopharyngeal ACE2 expression in

- those who tested negative for COVID-19 (P=0.092). Mean expression of transmembrane
- 69 (P=1·2e-4), soluble ACE2 (P<0·0001) and TMPRSS2 (P<0·0001) differed between COVID-19-

70 negative and -positive groups. In bivariate analysis of COVID-19-positive participants,

71 expression of transmembrane ACE2 positively correlated with SARS-CoV-2 RNA viral load

72 (P<0.0001), expression of soluble ACE2 negatively correlated (P<0.0001), and no correlation

73 was found with *TMPRSS2* (P=0.694). Multivariable analysis showed that the greatest viral RNA

14 loads were observed in participants with high transmembrane ACE2 expression (B=0.886,

75 95%CI:[0.596 to 1.18]), while expression of soluble ACE2 may protect against high viral RNA

76 load in the upper respiratory tract (B = -0.0990, 95% CI:[-0.176 to -0.0224]).

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 78 Interpretation

Nasopharyngeal *ACE2* expression plays a dual, contrasting role in SARS-CoV-2
infection of the upper respiratory tract. Transmembrane *ACE2* positively correlates, while
soluble *ACE2* negatively correlates with viral RNA load after adjusting for age, biological sex
and expression of TMPRSS2.

83

84 Funding

85 This project (COV-55) was funded by Genome British Columbia as part of their COVID86 19 rapid response initiative.

87

### 88 **Research in Context**

89

90 Evidence before this study

We conducted a MEDLINE <sup>®</sup> search using the MeSH topic terms: "angiotensin 91 92 converting enzyme 2 expression" and "SARS" and "age", restricting the search to English-93 language reports published from January 1<sup>st</sup>, 2020. The search returned n=98 articles, eighty-94 eight of which reported primary research; these were further filtered by the MeSH qualifiers 95 "epidemiology" and "virology" to provide n=43 articles. Search results were further restricted to 96 the MeSH headings: age, virus replication, host pathogen interactions, nasal mucosa, RNA viral 97 load and real-time polymerase chain reaction, which returned n=24 results. We read through the 98 abstracts of these twenty-four papers and manually selected n=4 for full review. This review 99 provided evidence that ACE2 expression is greater in the upper respiratory tract than the lower 100 respiratory tract, when measured by single-cell RNA sequencing, immunohistochemistry and 101 high-sensitivity RNA in-situ mapping. In the upper airway, ACE2 mRNA abundance closely 102 correlates with protein concentration. A reverse genetics study demonstrated that a variable 103 SARS-CoV-2 infection gradient occurs in the respiratory tract, with highest viral loads expected 104 in the upper airway. In several patient cohorts, upper respiratory expression of ACE2 was 105 significantly increased in those who smoke, in this analysis multivariable adjustment of age 106 suggested limited confounding. 107

It is made available under a CC-BY-NC-ND 4.0 International license .

108

### 109 Added Value of this study

110 We measured ACE2 expression in the context of COVID-19 testing to investigate the role 111 of nasopharyngeal ACE2 in SARS-CoV-2 infection. Our findings support previous work: the 112 strong correlation we observe between nasopharyngeal ACE2 expression and SARS-CoV-2 load 113 also suggests an infection gradient across the human airway. Greater viral loads are expected in 114 tissue with high transmembrane ACE2 expression. No observed relationship between age and 115 nasopharyngeal ACE2 in COVID-19-negative participants suggests that upper airway ACE2 116 expression is independent of the RAAS pathway. We are the first to measure endogenous 117 expression of soluble ACE2 in the upper airway of people tested for COVID-19 and include this 118 measure in multivariable analysis. Importantly, nasopharyngeal expression of soluble ACE2 119 negatively correlates with viral RNA load, inferring a protective role at the population level. 120

### 121 Implications of all the available evidence

Considering all available evidence, *ACE2* may play a dual, contrasting role in SARS-CoV-2 infection of the upper airway. Expression of transmembrane ACE2 positively correlates with SARS-CoV-2 RNA load, while expression of soluble ACE2 shows a negative association. Expression of nasopharyngeal ACE2 does not seem to correlate with age, as would be expected in the lower respiratory tract. Risk factors such as smoking may affect the baseline risk of high SARS-CoV-2 RNA loads in those infected. Factors associated with endogenous nasopharyngeal expression of soluble *ACE2* require further investigation.

129

### 130 Introduction

131 In December 2019, clusters of viral pneumonia were reported in Wuhan, China. A novel 132 highly pathogenic human coronavirus was isolated and named severe acute respiratory syndrome 133 coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease (COVID-19).<sup>1</sup> SARS-134 CoV-2 utilizes the same host receptor and protease for cell entry as the human coronaviruses 135 SARS-CoV and HCoV-NL63. The receptor angiotensin converting enzyme 2 (ACE2) mediates cellular entry, while transmembrane serine protease 2 (TMPRSS2) serves as a complementary 136 137 host factor.<sup>2,3</sup> In human physiology, ACE2 has a cardiovascular protective and anti-inflammatory role, as a constituent of the renin-angiotensin-aldosterone-system (RAAS).<sup>4</sup> Interestingly, 138

It is made available under a CC-BY-NC-ND 4.0 International license .

139 expression of ACE2 in the nasopharyngeal tract exceeds that in alveolar tissue, explaining initiation of SARS-CoV-2 infection in the upper respiratory tract.<sup>5</sup> Transcription of ACE2 140 141 produces at least two dominant mRNA transcripts responsible for translation into soluble and membrane-bound protein isoforms.<sup>6</sup> Although the transmembrane isoform has been shown to be 142 143 crucial for viral entry into host cells, the role of soluble ACE2 remains uncharacterized, though some evidence exists that it protects against SARS-CoV-2 infection.<sup>7,8</sup> Transmembrane serine 144 145 protease 2 (TMPRSS2) contributes to SARS-CoV-2 cell entry by cleaving the viral spike protein into a conformational form necessary for membrane fusion.<sup>2</sup> Unlike ACE2, TMPRSS2 expression 146 147 occurs more stably across upper airway tissue and alternative enzymes such as cathepsin B/L may perform its role in viral infection interchangeably.<sup>5</sup> To understand the importance of ACE2 148 149 expression in SARS-CoV-2 infection, we performed a cross-sectional study of people tested for 150 COVID-19 in British Columbia, Canada. The study aims to investigate the relationship between 151 i) nasopharyngeal expression of ACE2 and age in COVID-19-negative participants, ii) 152 nasopharyngeal expression of host genes by COVID-19 test result and iii) nasopharyngeal 153 expression of transmembrane ACE2 and viral RNA load in those who tested COVID-19-positive 154 adjusting for age, biological sex, expression of soluble ACE2 and TMPRSS2. Characterizing 155 expression of nasopharyngeal ACE2 in a large group of participants tested for COVID-19 will 156 increase our knowledge of host genes involved in viral infection and may allow for assessment 157 of baseline risk.

158

#### 159 Methods

160 Study Design and Participants

161 We performed cross-sectional sampling of people tested for COVID-19 at the British 162 Columbia Center for Disease Control Public Health Laboratory (BCCDC-PHL) from 24/3/2020-163 9/5/2020. At the time of sampling, provincial health guidelines required a clinical indication for 164 referral of a COVID-19 test. Inclusion criteria were applied to select study participants whose 165 diagnostic specimens were: tested centrally at the BCCDC-PHL, collected by nasopharyngeal 166 swab, the first test administered by provincial health number, suspended in Hologic Aptima<sup>TM</sup> 167 media, negative for concurrent Influenza A, B or Respiratory syncytia virus infection, stored at -168 80°C following RNA extraction and for whom host gene expression was successfully measured 169 by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). People meeting the

It is made available under a CC-BY-NC-ND 4.0 International license .

170 inclusion criteria (n=444), were excluded (n=16) if samples had a SARS-CoV-2 E gene cycle 171 threshold (Ct) value of >=38 by qRT-PCR. COVID-19-positive cases (n=212) were matched in a 172 1:1 ratio with those that tested negative for COVID-19 by age and biological sex (Figure S1). 173 Ethical approval for the study was obtained from the University of British Columbia 174 human ethics board (H20-01110). Demographic variables of age and biological sex were drawn 175 from public health laboratory data. Laboratory methods were performed in a College of 176 American Pathologists accredited laboratory with externally validated qRT-PCR assays. 9-12 177 178 Procedures Nasopharyngeal samples collected in Hologic Aptima<sup>TM</sup> media were stored at 4°C before 179 RNA extraction using the Viral RNA isolation kit on the MagMAX-96<sup>TM</sup> platform 180 181 (ThermoFisher).<sup>13</sup> 182 Host and viral gene targets were assayed by qRT-PCR on the Applied Biosystems 7500 183 Real-Time PCR platform using TaqMan FastVirus 1-step polymerase (ThermoFisher). Total 184 reaction volumes equaled 20ul, with 5ul of RNA template, 1ul of 20x primer/probe, 5ul Fast 185 Virus and 9*u*l of nuclease free water per reaction. Cycling conditions were set to: 50°C for 5 186 minutes, 95°C for 20 seconds followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 187 minute. A multiplex qRT-PCR reaction targeting SARS-CoV-2 envelope (E) and host ribonuclease P (RNaseP) was used to diagnosis acute viral infection by presence of viral RNA.<sup>14</sup> 188 Expression of RNaseP was used to ensure sample quality and control for sampling variation.<sup>14</sup> 189 190 Participants were diagnosed as COVID-19 positive with an E gene Ct value of <38. The E gene 191 Ct values were transformed to genome equivalents per millilitre by making a 5-fold, 1:10 192 standard curve of SARS-CoV-2 synthetic RNA- MN908947.3 (Twist Bioscience) (Table S1). 193 Commercially available primer probe sets were used to amplify the host gene targets TMPRSS2<sup>12</sup> (Hs00237175 m1) (ThermoFisher) and ACE2<sup>10</sup> (Hs01085333 m1, 194 195 HS01085340 m1) by multiplex qRT-PCR with a glyceraldehyde 3-phosphate dehydrogenase 196 (GAPDH) control<sup>11</sup> (Hs02758991\_g1) (ThermoFisher). Relative gene expression was calculated between TMPRSS2, ACE2 and GAPDH using the  $2^{-\Delta\Delta Ct}$  method.<sup>15</sup> Transmembrane ACE2 was 197 198 defined from the Hs01085333 m1 (ThermoFisher) gene target, which exon spans the 199 transmembrane domain. Soluble ACE2 was defined as absolute relative expression between the 200 Hs01085333\_m1 (ThermoFisher) and HS01085340\_m1 (ThermoFisher) gene targets (Figure

It is made available under a CC-BY-NC-ND 4.0 International license .

201 S3). The HS01085340 m1 target, does not include the transmembrane domain and is positioned 202 between two motifs essential for SARS-CoV receptor binding (Figure S3).

203 Statistical Analysis

204 De-identified data reporting participant COVID-19 test result, site of sample collection, 205 type of collection media, accessioning laboratory, age and biological sex was accessed from 206 public health laboratory records. Matching of COVID-19-positive people, who met the described 207 inclusion, exclusion criteria, to COVID-19-negative participants by age and biological sex in a 1:1 ratio was performed by a nearest neighbor algorithm (n=424).<sup>16</sup> Bivariate analysis was 208 209 performed between: age, biological sex, viral RNA load, TMPRSS2, soluble or transmembrane 210 ACE2, and COVID-19 test result. The balance of covariates between test groups was examined 211 post matching.

212 The relationship between age and nasopharyngeal expression of transmembrane ACE2 213 was examined in COVID-19-negative participants over the age of 18 by both linear regression 214 and categorization of age into 9-year intervals. Differences in ACE2 expression by age category 215 were tested by analysis of variance.

216 Differences in mean expression of host genes by COVID-19 diagnosis was further 217 examined by Levene's test for equal variance and a two-tailed, t-test assuming non-equal 218 variance.<sup>17</sup> Correlation between host gene expression and viral RNA load was analyzed by 219 simple linear regression. Multivariable analysis was performed by multiple linear regression, variable importance was assessed by the partial f-test.<sup>18</sup> Collinearity was examined by the 220 variable inflation factor with a cut-off of 10.<sup>19</sup> The common cause criterion was applied to 221 222 control for measured confounding, effect modification was incorporated when found statistically significant.<sup>20</sup> All analysis was performed in RStudio version 1.2.5042 using the packages: car, 223 ggsci, tidyverse, dataexplorer, ggpubr, lmtest, publish, forcats, matchit, tableone and effects.<sup>21</sup> 224 225

#### 226 Role of the Funding Source and Data Stewards

227 The funder and data stewards played no role in the study design, analysis or interpretation 228 of the results. As such, interpretation of the results does not reflect the views of the funding 229 organization or data stewards. The study was performed as research at the University of British 230 Columbia and British Columbia Centre for Disease Control.

231

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 232 **Results**

233	The analytic dataset contains an age- and biological sex-matched sample of n=424
234	participants tested for COVID-19 in British Columbia from 24/3/2020-9/5/2020 (Figure S1).
235	Participant characteristics are shown in Table 1. The mean age of n=212 COVID-19-positive
236	participants was 61.6, 47.6% were biologically male. In n=212 COVID-19-negative participants,
237	the mean age was 62.1, 48.6% were biologically male. Bivariate analysis between the examined
238	covariates and diagnosis (COVID-19-negative or -positive) shows balance of age (P= $0.83$ ) and
239	biological sex (P=0.92) between groups. Viral RNA (E gene Ct) was only detected in COVID-
240	19 positive participants, with an average Ct value of 28.2. Relative expression of transmembrane
241	ACE2, soluble ACE2, and TMPRSS2 statistically differed by COVID-19 test result (Table 1).
242	

#### 243 Table 1: Structure and Characteristics of Analytic Data Stratified by COVID-19 Test Result (n=424).

	COVID-19 Test Result					
Variable Name	Level	Total (n)	Negative	Positive	Chi X^2	T-Test
		424	212	212		
Age (mean [SD])		424	62.2 [24.3]	61.7 [23.5]		0.83
Sex (n [%])					0.92	
	Male	204	103 [48.6]	101 [47.6]		
	Female	220	109 [51.4]	111 [52.4]		
E Gene Ct (mean [SD])		424		28.2 [7.18]		
Transmembrane ACE2 (mean [SD])		424	(0.00) [1.08]	(-0.609) [1.90]		1.2e-4
Soluble ACE2 (mean [SD])		424	(0.00) [0.625]	(-0.898) [1.47]		< 0.0001
TMPRSS2 Total (mean [SD])		424	(0.00) [0.797]	(-1.35) [1.60]		< 0.0001

Participants who tested negative or positive by COVID-19 were matched by age and biological sex, balance was

245 checked between groups post matching by chi X^2 or t-test ( $\alpha$ =0.05). Relative gene expression of ACE2 and

246 TMPRSS2 was normalized to the negative group by the  $2^{-\Delta\Delta Ct}$  method. <sup>15</sup>

247

248 Relationship between ACE2 expression and age in COVID-19-negative participants

249 No relationship was found between nasopharyngeal ACE2 expression and age in COVID-

250 19 negative participants between 19 and 98 years of age with age as a continuous variable by

It is made available under a CC-BY-NC-ND 4.0 International license .

- 251 linear regression (P=0.076). This finding was reproduced when age was categorized into nine-
- 252 year intervals (P=0.092) (Figure 1).
- 253



254

255 Figure 1: Relationship between age and nasopharyngeal transmembrane ACE2 expression in COVID-19-256 negative participants. Boxplots of transmembrane ACE2 expression by nine-year age categories in COVID-19-257 negative participants between the ages of 19 and 98 (n=198); boxes represent the Q1-Q3 interquartile range, 258 whiskers represent 1.5x the Q1 or Q3 and horizontal lines the median transmembrane ACE2 expression by age 259 category. Nine-year categories were selected to optimize the distribution of observations between groups. 260 Participants who tested negative younger than 19 or older than 98 were excluded based on n<10 observations per 261 age group. No difference was detected in mean transmembrane ACE2 expression among age categories (ANOVA, 262 P=0.092).

263

264 Nasopharyngeal expression of ACE2 and TMPRSS2 by COVID-19 test result

Bivariate analysis showed a significant mean difference in transmembrane, soluble ACE2
and TMPRSS2 expression between COVID-19-negative and -positive participants (Figure 2).
These differences were further examined to detect non-equal variance for all host gene targets by
COVID-19 test result. Assuming non-equal variance, mean expression differed for

transmembrane ACE2 (P=1·2e-4), soluble ACE2 (P<0·0001) and TMPRSS2 (P<0·0001) between

It is made available under a CC-BY-NC-ND 4.0 International license .

- those testing COVID-19-negative or -positive (Figure 2). Expression of all three host genes was
- 271 lower in COVID-19-positive participants.





273 Figure 2: Relative nasopharyngeal gene expression of targeted host genes by COVID-19 test result. Gene

expression is portrayed in kernel density plots stratified by COVID-19 test result. Probability densities of relative

host gene expression are shown by positive (red, transmembrane ACE2; blue, soluble ACE2; yellow, TMPRSS2) and

276 negative COVID-19 test results (grey). Levene's test was used to detect non-equal variance in gene expression for

all host targets between COVID-19-negative and -positive participants. A two-tailed, t-test was used to examine

278 mean difference in host gene expression by COVID-19 test result assuming unequal variance: transmembrane ACE2

279 (P=1·2e-4), soluble ACE2 (P<0·0001) and TMPRSS2 (P<0·0001).

280

281 Association between host gene expression and viral RNA load in COVID-19-positive

282 participants

283 Correlations between each host gene and viral RNA load were examined by simple linear

- regression. Nasopharyngeal expression of transmembrane *ACE2* positively correlated with viral
- 285 RNA (P<0.0001). Expression of soluble *ACE2* negatively correlated with viral RNA
- (P<0.0001). No correlation was found between *TMPRSS2* expression and viral RNA (P=0.69)

It is made available under a CC-BY-NC-ND 4.0 International license .

287	(Figure S2). Multiple linear regression estimated that a one-unit change in transmembrane ACE2
288	expression increases viral RNA load by 0.886 Log10 GE/mL (95%CI: 0.596 to 1.18) adjusting
289	for age, biological sex, expression of soluble ACE2 and TMPRSS2 (Table 2). No collinearity was
290	detected between covariates. Biological sex could have been dropped from the model as evident
291	from comparison between nested models (P=0.76), but was kept for validity. A partial f-test
292	indicated effect modification between transmembrane and soluble $ACE2$ expression (P=0.010)
293	(Table 2). No effect modification was observed between transmembrane expression of ACE2 and
294	<i>TMPRSS2</i> (P= $0.23$ ). High expression of soluble <i>ACE2</i> decreases viral RNA load ( <i>B</i> = - $0.0990$ ,
295	95%CI: $[-0.176 \text{ to } -0.0224]$ ) (Table 2). The association between transmembrane ACE2
296	expression and viral RNA in nasopharyngeal tissue differs by the concomitant level of soluble
297	ACE2 expressed (Figure 3). Effect modification was visualized by categorizing soluble ACE2 by
298	the relative mean expression +/- 2 standard deviations of all study participants (Low= $-2.86$ ,
299	Mean= -0·444, High= 1·98, SD=2·43) (Figure 3).
300	
301	
302	
303	
304	
305	
306	
307	
308	
309	
310	
311	
312	
313	
314	
315	
316	
317	

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 318 Table 2: Unadjusted, Adjusted and Effect Modification Linear Regression Models of SARS-CoV-2 Viral

319 RNA Load

Variables	Unadjusted, B(95%CI)	Adjusted, B(95%CI)	Effect Modification, <i>B</i> (95%CI)
Intercept <sup>a</sup>	5.44 (5.12 to 5.77)	2.55 (1.71 to 3.40)	2.48 (1.65 to 3.31)
Transmembrane ACE2 Expression <sup>b</sup>	0.493 (0.329 to 0.656)	0.886 (0.596 to 1.18)	0.624 (0.274 to 0.975)
Soluble ACE2 Expression °		-0.243 (-0.494 to 0.00834)	-0.484 (-0.794 to - 0.174)
TMPRSS2 Expression <sup>d</sup>		-0.873 (-1.21 to -0.533)	-0.713 (-1.07 to -0.336)
Age <sup>e</sup>		0.0276 (0.0162 to 0.0389)	0.0259 (0.0146 to 0.0372)
Biological Sex <sup>f</sup>		0.0778 (-0.424 to 0.579)	0.0735 (-0.422 to 0.569)
Transmembrane ACE2* Soluble ACE2 Expression <sup>g</sup>			-0.0990 (-0.176 to -0.0224)

320 Regression of SARS-CoV-2 viral RNA load by Transmembrane ACE2, Soluble ACE2 and TMPRSS2 Expression,

321 Age and Biological Sex.

322 <sup>a</sup> Viral RNA load in females, measured by  $Log_{10}$  viral genome equivalents per millilitre ( $Log_{10}$  GE/mL) targeting the

323 SARS-CoV-2 *E* gene.

<sup>b</sup> Transmembrane ACE2 Expression  $(2^{-\Delta\Delta Ct})$  in the nasopharyngeal epithelium of SARS-CoV-2 positive participants.

325 <sup>c</sup> Soluble *ACE2* expression  $(2^{-\Delta\Delta Ct})$  in the nasopharyngeal epithelium of SARS-CoV-2 positive participants.

326 <sup>d</sup> *TMPRSS2* expression (2<sup>- $\Delta\Delta$ Ct</sup>) in the nasopharyngeal epithelium of SARS-CoV-2 positive participants.

- <sup>e</sup>Age, measured in years.
- 328 <sup>f</sup>Biological sex, effect of being male.

329 <sup>g</sup> Effect modification term, the effect of transmembrane ACE2 expression on viral RNA load differs by expression of

- soluble ACE2.
- 331
- 332

It is made available under a CC-BY-NC-ND 4.0 International license .



333

334 Figure 3: The association between transmembrane ACE2 expression and SARS-CoV-2 RNA load in

335 nasopharyngeal tissue differs by the amount of soluble ACE2 expression. Soluble ACE2 expression was

categorized into low, mean and high levels to demonstrate the relationship. The low category (grey) represents

337 soluble ACE2 expression two standard deviations below the mean expression. The mean category (orange) codes for

the mean soluble *ACE2* expression, zero standard deviations. The high category (blue) indicates soluble *ACE2* 

expression two standard deviations above mean expression. Shaded areas represent 95% confidence intervals, solid

- 340 lines represent *B* coefficients from multiple linear regression.
- 341

### 342 Discussion

In the described study, we measured nasopharyngeal *ACE2* and *TMPRRS2* relative gene expression by qRT-PCR in a cross-sectional sample of n=424 participants tested for COVID-19 in British Columbia. Analysis was performed to understand: the relationship between *ACE2* expression and age in COVID-19-negative participants, differences in host gene expression between COVID-19-negative and -positive participants and the role of *ACE2* in SARS-CoV-2

It is made available under a CC-BY-NC-ND 4.0 International license .

infection in those who tested positive for COVID-19.

349 Among participants tested negative for COVID-19, we found no relationship between 350 nasopharyngeal ACE2 expression and age, in a group of adults between 19-98 years of age. This 351 result, agrees with findings from other efforts to characterize nasopharyngeal ACE2 expression at 352 the population level. Bunyavanich et al. reported a difference in ACE2 expression levels between children younger than ten years old and young adults from eighteen to twenty-four years old.<sup>22</sup> 353 354 No difference was evident between young adults, and adults twenty-five or more years in age.<sup>22</sup> 355 Lack of a relationship between nasopharyngeal ACE2 expression and progressive aging suggests 356 that expression of ACE2 in the upper airway does not correlate with expression of ACE2 in the 357 RAAS. The physiological importance of ACE2 in the RAAS suggests that its expression would 358 increase in response to age as older people have higher prevalence of cardiovascular disease or similar comorbidities (i.e. diabetes).<sup>23</sup> If nasopharyngeal expression of ACE2 occurs 359 360 independently of the RAAS pathway, future studies should ascertain what factors if any regulate 361 expression of soluble ACE2 in nasopharyngeal tissue and variation of ACE2 expression in 362 COVID-19-negative people over time. Some populations, such as young children, may have 363 differential levels of nasopharyngeal ACE2 expression which protect against SARS-CoV-2 viral infection.22,24 364

365 Participants who tested positive for COVID-19 were matched to those who tested 366 negative by age and biological sex to estimate the direct relationship between host gene expression and SARS-CoV-2 test result. This analysis demonstrated that mean expression of 367 368 transmembrane, soluble ACE2 and TMPRSS2 decreased in COVID-19-positive participants, 369 while variation increased. Unfortunately, the limitation of reverse-causality in cross-sectional 370 study design prevents us from understanding whether the presence of SARS-CoV-2 in positive 371 samples affects host gene expression or host gene expression puts people at risk of viral 372 infection. However, if we make the plausible assumption that at least a single round of viral 373 replication must occur in order for qRT-PCR to generate a positive test result, it suggests that the 374 observed variation in host gene expression of participants who test positive for COVID-19 375 results from viral replication.<sup>25</sup> Numerous studies have demonstrated that coronavirus 376 replication disrupts cellular transcription, as resources required by the cell to produce mRNA are 377 instead sequestered by virus to replicate its genome.<sup>26</sup> Reduced transcription of ACE2 by 378 SARS-CoV, but not HCoV-NL63, in an *in vitro* model of Vero E6 cell infection was previously

It is made available under a CC-BY-NC-ND 4.0 International license .

suggested as a pathological mechanism.<sup>3</sup> Putative SARS-CoV-2 disruption of *ACE2* expression
could partially explain the apparent association between hypertension, diabetes, and severe
COVID-19.<sup>27</sup> Answering these questions; however, requires a longitudinal study design to test
the temporal effect of SARS-CoV-2 replication on the expression of *ACE2* and other implicated
host genes.

384 The sample was then restricted to participants who tested positive for COVID-19 to 385 investigate the association between nasopharyngeal ACE2 expression and SARS-CoV-2 RNA 386 load. Bivariate and multivariable analysis both suggest that ACE2 plays a dual, contrasting role 387 in SARS-CoV-2 infection. Transmembrane ACE2 positively correlates with viral RNA load, 388 while soluble ACE2 may limit viral infection by reducing viral RNA load. Interestingly, effect 389 modification was observed between transmembrane and soluble ACE2 implicating that the 390 proportion between these molecules may have more importance than absolute expression of 391 either individually. For example, between two people with similar above-average 392 nasopharyngeal transmembrane ACE2 expression, we would expect a higher viral RNA load in 393 the one with lower soluble ACE2 expression. Though we are not equipped to characterize the 394 mechanism by which soluble ACE2 plays a protective role in SARS-CoV-2 infection, 395 identification of this effect at the population level warrants further investigation of the 396 underlying mechanism. Previous work has postulated that soluble ACE2 restricts SARS-CoV/SARS-CoV-2 infection by acting as a decoy substrate.<sup>28</sup> In a study of virus-ACE2 dynamics 397 398 in engineered human tissue, instead of binding to transmembrane ACE2, virus particles bound to soluble ACE2 and were unable to infect susceptible cells.<sup>28</sup> Moreover, recombinant soluble 399 ACE2 was recently administered to a COVID-19 patient requiring ventilation.<sup>8</sup> In the case report, 400 401 administration of soluble ACE2 decreased viral RNA load in the patient's plasma, tracheal 402 aspirate and nasopharyngeal specimens. Additionally, soluble ACE2 did not interfere with 403 production of IgG and assumed its cardiovascular protective role in the RAAS.<sup>8</sup> 404 Soluble ACE2 may also influence the usage of Neuropilin-1 as a co-receptor or 405 alternative receptor for SARS-CoV-2. Function of Neuropilin-1 for cell entry and infectivity may 406 depend upon high SARS-CoV-2 viral load; therefore, expression of soluble ACE2 may limit SARS-CoV-2 tropism.<sup>29</sup> 407

408 We acknowledge that the described study has several limitations. In our sample, the age 409 distribution possesses a left skew which prevents us from examining the relationship between

It is made available under a CC-BY-NC-ND 4.0 International license .

410 age and nasopharyngeal expression of ACE2 in participants younger than 18 years of age. The 411 difference in mean host gene expression observed between participants who tested negative or 412 positive for COVID-19 cannot be resolved in a cross-sectional study design due to reverse 413 causality. We attempted to control for immunological gene regulation by excluding people with 414 endemic respiratory co-infections from Influenza A/B or Respiratory syncytia virus. We describe 415 associations between transmembrane, soluble ACE2 and SARS-CoV-2 RNA load which suggest 416 the dual, contrasting role of ACE2 in viral infection. However, we cannot provide evidence of the 417 mechanism responsible for this association. Additionally, the measure of viral RNA load over-418 approximates infectious viral titre and viral RNA may be isolated in the absence of infectious virus.<sup>30</sup> 419 420 In conclusion, we have characterized nasopharyngeal ACE2 expression in a sample of 421 people tested for COVID-19. Analysis shows no relationship between age and nasopharyngeal 422 ACE2 expression in COVID-19-negative participants 19-98 years old. Expression of

423 nasopharyngeal *ACE2* and *TMPRSS2* differs between COVID-19-positive and –negative groups.

424 The role of nasopharyngeal ACE2 in SARS-CoV-2 infection of the upper-airway may be

425 differentiated by gene isoform expression; transmembrane ACE2 positively correlates with viral

426 RNA load, while soluble *ACE2* shows a negative association. Nasopharyngeal expression of

427 ACE2 possesses a dual, contrasting role in SARS-CoV-2 infection at the population level.

428

#### 429 **Contributors**

430 AMN, DDWT, KSK, NAP, ANJ, MK, DMP, and IS conceived, designed, and obtained funding

431 for the project. AMN wrote the manuscript, editing was provided by Karen Chu. AMN, DDWT

432 and KSK performed the experiments. CDL and HS obtained and cleaned laboratory data. AMN,

433 KSK, DDWT, CAB, CDL, and HS analyzed the data under the direction of CS, NAP, ANJ, MK,

434 DMP and IS. All authors interpreted the data, edited the manuscript and provided their approval435 to publish.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 437 **Declaration of Interests**

- 438 The authors have no conflicts of interest to declare.
- 439

### 440 Acknowledgments

- 441 We would like to acknowledge the work of all our clinical colleagues at the British
- 442 Columbia Centre for Disease Control and across the globe in responding to the COVID-19
- 443 pandemic. This work would not have been possible without funding from Genome British
- 444 Columbia. We would like to thank Michael Donoghue for managing this multi-stakeholder
- 445 project and Karen Chu for assisting as a medical copy editor.
- 446

### 447 **References**

- 448
- Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in
  China, 2019. *N Engl J Med* 2020; **382**: 727–33.
- 451 2 Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 Cell Entry Depends on
- 452 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;
  453 181: 271-280.e8.
- Glowacka I, Bertram S, Herzog P, *et al.* Differential Downregulation of ACE2 by the
  Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human
  Coronavirus NL63. *J Virol* 2010; **84**: 1198–205.
- 457 4 South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular
  458 consequences. *Am J Physiol Circ Physiol* 2020; **318**: H1084–90.
- 459 5 Sungnak W, Huang N, Bécavin C, *et al.* SARS-CoV-2 entry factors are highly expressed
  460 in nasal epithelial cells together with innate immune genes. *Nat Med* 2020; 26: 681–7.
- 461 6 Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of
- 462 ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett* 2002; **532**: 107–
  463 10.
- 464 7 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of

It is made available under a CC-BY-NC-ND 4.0 International license .

465		SARS-CoV-2 by full-length human ACE2. Science (80-) 2020; 367: 1444-8.
466	8	Zoufaly A, Poglitsch M, Aberle JH, et al. Human recombinant soluble ACE2 in severe
467		COVID-19. Lancet Respir Med 2020; published online Sept. DOI:10.1016/S2213-
468		2600(20)30418-5.
469	9	Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV)
470		by real-time RT-PCR. Eurosurveillance 2020; 25. DOI:10.2807/1560-
471		7917.ES.2020.25.3.2000045.
472	10	Messmann R, Dietl A, Wagner S, et al. Alterations of the renin angiotensin system in
473		human end-stage heart failure before and after mechanical cardiac unloading by LVAD
474		support. Mol Cell Biochem 2020; 472: 79–94.
475	11	Kitajima T, Okita Y, Kawamura M, et al. The relationship between preoperative T helper
476		cytokines in the ileal mucosa and the pathogenesis of pouchitis. BMC Gastroenterol 2020;
477		<b>20</b> : 277.
478	12	Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer cell-surface
479		TMPRSS2 to endosomal cathepsins for cell entry. Virology 2018; 517: 9–15.
480	13	Hologic. Instructions for Using the Aptima Swab Specimen Collection Kit for Patient-
481		Collected Specimens. 2020.
482	14	LeBlanc JJ, Gubbay JB, Li Y, et al. Real-time PCR-based SARS-CoV-2 detection in
483		Canadian laboratories. J Clin Virol 2020; 128: 104433.
484	15	Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time
485		Quantitative PCR and the $2-\Delta\Delta CT$ Method. <i>Methods</i> 2001; <b>25</b> : 402–8.
486	16	Ho DE, Imai K, King G, Stuart EA. MatchIt : Nonparametric Preprocessing for Parametric
487		Causal Inference. J Stat Softw 2011; 42. DOI:10.18637/jss.v042.i08.
488	17	Gastwirth JL, Gel YR, Miao W. The Impact of Levene's Test of Equality of Variances on
489		Statistical Theory and Practice. Stat Sci 2009; 24: 343-60.
490	18	Jamshidian M, Jennrich RI, Liu W. A study of partial F tests for multiple linear regression
491		models. Comput Stat Data Anal 2007; <b>51</b> : 6269–84.
492	19	Fox J, Monette G. Generalized Collinearity Diagnostics. J Am Stat Assoc 1992; 87: 178.
493	20	VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol 2019; 34: 211–9.
494	21	Rstudio Team. RStudio. 2019.
495	22	Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting

It is made available under a CC-BY-NC-ND 4.0 International license .

496		Enzyme 2 in Children and Adults. JAMA 2020; published online May 20.
497		DOI:10.1001/jama.2020.8707.
498	23	Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in
499		COVID-19. Crit Care 2020; 24: 422.
500	24	Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China.
501		Pediatrics 2020; 145: e20200702.
502	25	Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (COVID-19) by the numbers.
503		Elife 2020; 9. DOI:10.7554/eLife.57309.
504	26	Nakagawa K, Lokugamage KG, Makino S. Viral and Cellular mRNA Translation in
505		Coronavirus-Infected Cells. 2016: 165–92.
506	27	Obukhov AG, Stevens BR, Prasad R, et al. SARS-CoV-2 Infections and ACE2: Clinical
507		Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes.
508		Diabetes 2020; 69: 1875–86.
509	28	Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in Engineered
510		Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell 2020; 181: 905-913.e7.
511	29	Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell
512		entry and infectivity. Science (80-) 2020; : eabd2985.
513	30	Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory
514		Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis 2020; published
515		online May 22. DOI:10.1093/cid/ciaa638.
516		
517		
518		
519		
520		
521		
522		
523		

It is made available under a CC-BY-NC-ND 4.0 International license .

## 524 Supplementary Material



Study Participants

- 526 Figure S1: Inclusion, exclusion criteria applied to all people tested for COVID-19 in British 527 Columbia from 24/3/2020-9/5/2020 to select study participants (analytic data). Specimens from people 528 tested for COVID-19 with the following criteria were included (white box): tested at the BCCDC-PHL, 529 specimen was collected by nasopharyngeal swab, test was the primary test by provincial health number, 530 specimen was suspended in Hologic Aptima<sup>TM</sup> media and stored at -80°C following testing, negative for 531 Influenza A, B or Respiratory syncytia virus infection and possessing host gene expression data. Those 532 with a COVID-19-positive diagnosis, were further restricted by excluding (grey box) SARS-CoV-2 E gene 533 Ct values of > 38 by qRT-PCR (n=212), and matched in a 1:1 ratio with COVID-19-negative people 534 (n=212) by age and biological sex (bold text). 535
- 536
- 537
- 538
- 550
- 539

It is made available under a CC-BY-NC-ND 4.0 International license .







<sup>543</sup> RNA load. The level of transmembrane ACE2 (red), soluble ACE2 (blue) and TMPRSS2 (black) expression in

- 545 millilitre (GE/mL). Host gene expression was measured by quantitative real-time PCR and normalized to expression
- of the housekeeping gene GAPDH by the  $(2^{-\Delta\Delta Ct})$  method. Soluble ACE2 was defined as absolute relative expression
- between the Hs01085333\_m1 (ThermoFisher) and HS01085340\_m1 (ThermoFisher) gene targets (Figure S3).

<sup>544</sup> positive cases of COVID-19 and its relationship with SARS-CoV-2 RNA is shown in Log<sub>10</sub> genome equivalents per

It is made available under a CC-BY-NC-ND 4.0 International license .

- 548 Simple linear regression was used estimate correlations, the reported P values are for the Beta-coefficients of host
- 549 gene expression.
- 550

#### 551 Table S1: Serial Dilution of SARS-CoV-2 RNA for Generation of a Standard Curve by Quantitative Real-

552 Time Polymerase Chain Reaction.

Log <sub>10</sub> Dilution	10^0	10^1	10^2	10^3	10^4
~GE/mL <sup>t</sup>	1	10	100	1000	10,000
R1	36.1	32.6	28.9	25.9	22.8
R2	35.8	31.9	28.8	25.8	22.8
R3	34.8	32.3	28.8	25.8	22.8
R4	35.6	31.7	28.8	25.7	22.8
R5	34.5	31.9	28.6	25.7	22.3
R6	34.0	32.1	28.7	25.5	22.7
<b>R7</b>	34.4	31.9	28.6	25.6	22.8
<b>R8</b>	34.1	31.4	28.8	25.6	22.8
R9	34.7	31.4	28.7	25.6	22.9

553 a 5-fold, 1:10 serial dilution of SARS-CoV-2 synthetic RNA was performed over nine independent replicates (n=9)

to measure a standard curve by quantitative real-time PCR targeting the viral E gene.

555  $\tau$  a simple linear regression model was fit to n=9 replicates of the SARS-CoV-2 RNA standard curve: GE/mL=b<sub>0</sub> +

556  $b_1x_1$ . Where, Genome Equivalents per millilitre (GE/mL) = 34.5 -1.27ln(x) and R^2 = 0.999.

It is made available under a CC-BY-NC-ND 4.0 International license .

Homo sapiens angiotensin I converting enzyme 2 (ACE2), transcript variant 2, mRNA NCBI Reference Sequence: NM\_021804.3

5' 1	ggcactcata	catacactct	ggcaatgagg	acactgagct	cgcttctgaa	atttgacaag		
61	ataaccacta	aaatctcttt	gaattctatg	ttgttgtgat	cccatggcta	cagaggatca		
121	ggagttgaca	tagatactct	ttggatttca	taccatotoo	aggetttett	acttocacgt		
1.81	gacettgact	gagttttgaa	tagggggggaa	cccaadttca	aggeotecte	2020202090		
241	tataataaaa	agetttagat	ctogggggggg	teatteaata	aatataatat	taaataaaaa		
291	ccccacyayy	ayyuuuayu	ctayyyaaay	ctattcayty	gaugugaucu	tygettatag		
301	gggacgatgt	caagetette	ctggctcctt	ctcagccttg	ttgctgtaac	tgctgctcag		
301	tecaccattg	aggaacaggc	caagacattt	ttggacaagt	ttaaccacga	ageegaagae		
421	ctgttctatc	aaagttcact	tgcttcttgg	aattataaca	ccaatattac	tgaagagaat		
481	gtccaaaaca	tgaataatgc	tggggacaaa	tggtctgcct	ttttaaagga	acagtccaca		
541	cttgcccaa <mark>a</mark>	tgtatccact	acaagaaatt	cagaatctca	cagtcaagct	tcagctgcag		
601	gctcttcagc	aaaatgggtc	ttcagtgctc	tcagaagaca	agagcaaacg	gttgaacaca		
661	attctaaata	caatgagcac	catctacagt	actggaaaag	tttgtaaccc	agataatcca		
721	caagaatgct	tattacttga	accaggtttg	aatgaaataa	tggcaaacag	tttagactac		
781	aatgagaggc	tctgggcttg	ggaaagctgg	agatctgagg	tcggcaagca	gctgaggcca		
841	ttatatgaag	agtatgtggt	cttgaaaaat	gagatggcaa	gagcaaatca	ttatgaggac		
901	tatggggatt	attggagagg	agactatgaa	gtaaatgggg	tagatggcta	tgactacage		
961	cacaaccaat	tgattgaaga	tgtggaacat	acctttgaag	agattaaacc	attata <mark>tgaa</mark>		
1021	catetteate	cctatgtgag	ggcaaagttg	atgaatgoot	atcottocta	tatcagtoca		
1021	attggatgcc	tecetactes	tttacttaat	gatatotogo	ateaettta	gacaaatotg		
1141	tootottto	constrant	taassasassa	gatatgeggg	gtagatttg	gacaaatcety		
1001	Lactettga	Cagilleett	Lygacagaaa	CCaaacatag	algulaciga	tycaatyyty		
1201	gaccaggeet	gggatgcaca	gagaatatte	aaggaggeeg	agaagttett	tgtatctgtt		
1261	ggtcttccta	atatgactca	aggattctgg	gaaaattcca	tgctaacgga	cccaggaaat		
1321	gttcagaaag	cagtctgcca	tcccacagct	tgggacctgg	ggaagggcga	<b>cttcagg</b> atc		
1381	cttatgtgca	caaaggtgac	aatggacgac	ttcctgacag	ctcatcatga	gatggggcat		
1441	atccagtatg	atatggcata	tgctgcacaa	ccttttctgc	taagaaatgg	agctaatgaa		
1501	ggattccatg	aagctgttgg	ggaaatcatg	tcactttctg	cagccacacc	taagcattta		
1561	aaatccattg	gtcttctgtc	acccgatttt	caagaagaca	atgaaacaga	aataaacttc		
1621	ctgctcaaac	aagcactcac	gattgttggg	actctgccat	ttacttacat	gttagagaag		
1681	tqqaqqtqqa	tggtctttaa	aggggaaatt	cccaaaqacc	agtggatgaa	aaagtggtgg		
1741	gagatgaagc	gagagatagt	taaaataata	gaacctgtgc	cccatgatga	aacatactgt		
1801	gaccccgcat	ctctgttcca	tatttctaat	gattactcat	tcattcgata	ttacacaagg		
1861	accetttace	aattccagtt	tcaagaagca	ctttatcaaa	canctaaaca	tgaaggccct		
1921	ctgcacaaat	ataacatoto	aaactotaca	gaagetggaag	ageaactatt	caatatacta		
1981	aggettggaa	aatcagaacc	ctggaccota	gaageeggae	atattataaa	adcasadaac		
2041	aggeeeggaa	aaccagtact	cooggacceta	goaccestat	ttootage	ageaaagaac		
2101	acyaacycaa	ggccactgct	caactacttt	gagecettat	cototogoco	gaaagaccag		
2101	aacaayaatt	CLLLLGLGGG	atggagtacc	gactggagtc	Catatycaya	ccaaagcate		
2101	aaagtgagga	taageetaaa	atcagetett	ggagataaag	catatgaatg	gaacgacaat		
2221	gaaatgtacc	tgttccgatc	atctgttgca	tatgetatga	ggcagtactt	tttaaaagta		
2281	aaaaatcaga	tgattcttt	tggggaggag	gatgtgcgag	tggctaattt	gaaaccaaga		
2341	atctccttta	atttctttgt	cactgcacct	aaaaatgtgt	ctgatatcat	tcctagaact		
2401	gaagttgaaa	aggccatcag	gatgtcccgg	agccgtatca	atgatgcttt	ccgtctgaat		
2461	gacaacagcc	tagagtttct	ggggatacag	ccaacacttg	gacctcctaa	ccagccccct		
2521	gtttccatat	ggctgattgt	ttttggagtt	gtgatgggag	tgatagtggt	tggcattgtc		
2581	atcctgatct	tcactgggat	cagagatcgg	aagaagaaaa	ataaagcaag	aagtggagaa		
2641	aatccttatg	cctccatcga	tattagcaaa	ggagaaaata	atccaggatt	ccaaaacact		
2701	gatgatgttc	agacctcctt	ttagaaaaat	ctatgttttt	cctcttgagg	tgattttgtt		
2761	gtatgtaaat	gttaatttca	tggtatagaa	aatataagat	gataaagata	tcattaaatg		
2821	tcaaaactat	gactctgttc	agaaaaaaaa	ttgtccaaag	acaacatggc	caaqqaqaqa		
2881	gcatcttcat	tgacattgct	ttcagtattt	atttctgtct	ctggatttga	cttctattct		
2941	gtttcttaat	aaggattttg	tattagagta	tattagggaa	agtgtgtatt	tggtctcaca		
3001	gactattcag	ggataatcta	aatotaaato	tctattaaat	ttctgaagtt	naaaacaann		
30.61	atatatcatt	qqaqcaaqtq	ttagatetta	tatggaatat	agatagatca	cttataaqqa		
3121	cagtacctag	gaactagtat	adctacaada	attgagaatg	ggatggatta	actcactttc		
31.81	atttaatcca	ttatcaaaaa	taacatactt	tetteacant	aactcaattc	aagtactatg		
3241	atastttaaa	tagaataata	tttaasstaa	atesteettt	attoppata	aagcaccacg		
2201	gugattuget	cacagigaig	coccetacco	accatgettt	ttosattosa	acayyttaa		
3301	agagagaaga	atccagggaa	caggtagagg	acattgettt	ttcacttcca	aggtgcttga		
3361	tcaacatctc	cctgacaaca	caaaactaga	gccagggggcc	tccgtgaact	cccagagcat		
3421	gcctgataga	aactcatttc	tactgttctc	taactgtgga	gtgaatggaa	attccaactg		
3481	tatgttcacc	ctctgaagtg	ggtacccagt	ctcttaaatc	ttttgtattt	gctcacagtg		
3541	tttgagcagt	gctgagcaca	aagcagacac	tcaataaatg	ctagatttac	acactc 3'		
end:								
ismembrane Domain								
S-CoV Binding Domain								
2 450100	5222 m1 2'							
-2 1130108			_					
	s.//www.themonishen.com/older/genome-							
loase/rpearUXversuffix=pearUX2&elcanoForm=true#!/ge/assays/ge_all/rkeyword=HS01085333_m1								
-2 HS0108	5340_m1 5'		_					
s://www.thermofisher.com/order/genome-								
abase/?pe	arUXVerSuffix=p	earUX2&elcanoF	orm=true#!/ge/	assays/ge_all/?k	eyword=HS0108	5340 m1		
			10-7					

558

559

560 Figure S3: Nasopharyngeal expression of ACE2 was determined by two quantitative real-time polymeras				
	560	Figure S3: Nasopharyngeal expression of ACE2 v	was determined by two quantitative real-time polyn	nerase

### 561 chain reaction targets, one target (yellow) exon spans the ACE2 transmembrane domain. The other does not

- 562 include the transmembrane domain (pink) and lays nested between two motifs known to interact with the SARS-
- 563 CoV receptor binding domain (blue). The measure of soluble ACE2 represents normalized expression of the pink to
- 564 yellow target, or the proportion of non-transmembrane ACE2 to transmembrane ACE2.

Leg Trai SAR ACE http data ACE

http